Duration and Efficacy of Azstarys (serdexmethylphenidate and dexmethylphenidate) on Adult ADHD Symptoms and Executive Function In Early Evening

Brief description of study

The purpose of this open-label treatment study is to extend the safety and efficacy evidence basis for Azstarys, a recently FDA approved ADHD product, in adults with ADHD and study adult executive functions throughout the day into early evening. Subjects will be in the study for approximately 8 weeks; 0-3 weeks (screening) 2 weeks (observation stabilization period) and 3 weeks (open-label azstarys / serdmph).

Clinical Study Identifier: s22-01003
ClinicalTrials.gov Identifier: NCT06000501
Principal Investigator: Lenard A Adler.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.